|
|
 |
|
|
|
Product Portfolio
|
|
|
|
|
|
Giaconda’s products are targeted towards the treatment of conditions that are not adequately addressed by existing therapy. The products are underpinned by the scientific rationale that many gastrointestinal conditions are caused by infection. The Giaconda portfolio consists of four therapeutic products and a pre-colonoscopy bowel preparation, all of which are novel combinations of known compounds. The novelty of the Giaconda products, and the basis of their patent position, lies in the originality of these combinations and the clinical benefits which they have already demonstrated.
|
Product
|
Targeted Disease Indication
|
Clinical Trial – Next Step
|
| Myoconda |
Crohn’s Disease |
Commencing Phase III |
| Hepaconda |
Hepatitis C Virus |
Commencing Phase II |
| Heliconda |
Resistant Helicobacter pylori infection |
Commencing Phase III |
| Ibaconda |
Constipation – predominant Irritable Bowel Syndrome |
Commencing Phase II |
| Picoconda |
Bowel Preparation for colonoscopy |
Commencing Phase III |
The Giaconda product pipeline was developed by Prof. Borody at the Centre for Digestive Diseases. In addition to the existing pipeline, Giaconda has been granted an option and first right of refusal to acquire all other current and future intellectual property developed by the Centre for Digestive Diseases or Prof. Borody in the area of digestive disease therapies. In this way Giaconda has secured a valuable pipeline of future products for the Company.
|
|
|
|
|
|
|
|
|
